An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors.

J Am Chem Soc
Authors
Keywords
Abstract

An aldol-based build/couple/pair (B/C/P) strategy was applied to generate a collection of stereochemically and skeletally diverse small molecules. In the build phase, a series of asymmetric syn- and anti-aldol reactions were performed to produce four stereoisomers of a Boc-protected γ-amino acid. In addition, both stereoisomers of O-PMB-protected alaninol were generated to provide a chiral amine coupling partner. In the couple step, eight stereoisomeric amides were synthesized by coupling the chiral acid and amine building blocks. The amides were subsequently reduced to generate the corresponding secondary amines. In the pair phase, three different reactions were employed to enable intramolecular ring-forming processes: nucleophilic aromatic substitution (S(N)Ar), Huisgen [3+2] cycloaddition, and ring-closing metathesis (RCM). Despite some stereochemical dependencies, the ring-forming reactions were optimized to proceed with good to excellent yields, providing a variety of skeletons ranging in size from 8- to 14-membered rings. Scaffolds resulting from the RCM pairing reaction were diversified on the solid phase to yield a 14 400-membered library of macrolactams. Screening of this library led to the discovery of a novel class of histone deacetylase inhibitors, which display mixed enzyme inhibition, and led to increased levels of acetylation in a primary mouse neuron culture. The development of stereo-structure/activity relationships was made possible by screening all 16 stereoisomers of the macrolactams produced through the aldol-based B/C/P strategy.

Year of Publication
2010
Journal
J Am Chem Soc
Volume
132
Issue
47
Pages
16962-76
Date Published
2010 Dec 01
ISSN
1520-5126
DOI
10.1021/ja105119r
PubMed ID
21067169
PubMed Central ID
PMC3004530
Links
Grant list
P50 GM069721-01 / GM / NIGMS NIH HHS / United States
1R01DA028301-01 / DA / NIDA NIH HHS / United States
R01 DA028301-02 / DA / NIDA NIH HHS / United States
P50 GM069721 / GM / NIGMS NIH HHS / United States
R01 DA028301 / DA / NIDA NIH HHS / United States